Conversely, therapeutic exploitation of the TNF–TNFR axis has led to effective drugs such as adalimumab and etanercept for autoimmune diseases as well as promising antitumor agents targeting the costimulatory immune receptors1,2. The gene discussed is TNF; the disease is autoimmune disease.